Ask AI
ProCE Banner Activity

My Thoughts on the Clinical Implications of the Expanded Indication for Niraparib

Clinical Thought
Gain expert insights from Kathleen Moore, MD, on key findings from the QUADRA trial that led to FDA label expansion of niraparib in ovarian cancer.

Released: November 26, 2019

Share

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

Supported by independent educational grants from

Clovis Oncology

Tesaro

Faculty Disclosure

Primary Author

Kathleen N. Moore, MD, MS, FASCO

Deputy Director and Director of Phase 1
Fred and Pamela Buffett Cancer Center at the University of Nebraska Medical Center
Omaha, Nebraska
ASCO BOD
GOG F BOD

Kathleen Moore, MD, has disclosed that she has received consulting fees from Aravive, AstraZeneca, Clovis, Cue Biopharma, Genentech/Roche, Merck, OncoMed, Pfizer, Samumed, Tesaro, and VBL Therapeutics.